NEWTON-EVERETT, LLC – Trademark Portfolio
Entity Type: 16
NEWTON-EVERETT, LLC holds 34 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 34 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 21 trademarks are registered. Notable registered marks include CELEXIL, OXOTRIM, RELËVIA, RETENIX, and SENSTRA. The owner is based in Scottsdale, AZ.
9160 E. Bahia Dr., Suite 200
Scottsdale, AZ 85260
Showing of trademarks Trademarks
Trademark Classifications
NEWTON-EVERETT, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does NEWTON-EVERETT, LLC have?
NEWTON-EVERETT, LLC has 34 U.S. trademarks filed with the USPTO. Of these, 21 registered, 3 abandoned, 10 cancelled.
What trademark classes does NEWTON-EVERETT, LLC file in?
NEWTON-EVERETT, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are NEWTON-EVERETT, LLC's most well-known trademarks?
NEWTON-EVERETT, LLC's registered trademark portfolio includes well-known marks such as CELEXIL, OXOTRIM, RELËVIA, RETENIX, and SENSTRA. These are among 21 currently registered trademarks in the portfolio.
What is NEWTON-EVERETT, LLC's trademark registration success rate?
NEWTON-EVERETT, LLC has a 62% trademark registration rate, with 21 out of 34 resolved applications resulting in successful registration. Currently, 0 applications are pending review.